Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

A longitudinal analysis of the completeness of maternal HIV testing, including repeat testing in Cape Town, South Africa.

de Beer S, Kalk E, Kroon M, Boulle A, Osler M, Euvrard J, Timmerman V, Davies MA.

J Int AIDS Soc. 2020 Jan;23(1):e25441. doi: 10.1002/jia2.25441.

2.

Loss to follow-up from antiretroviral therapy clinics: A systematic review and meta-analysis of published studies in South Africa from 2011 to 2015.

Kaplan S, Nteso KS, Ford N, Boulle A, Meintjes G.

South Afr J HIV Med. 2019 Dec 18;20(1):984. doi: 10.4102/sajhivmed.v20i1.984. eCollection 2019.

3.

Safety and Effectiveness of Isoniazid Preventive Therapy in HIV-Positive Pregnant Women on Art: An Observational Study using Linked Population Data.

Kalk E, Heekes A, Mehta U, de Waal R, Jacob N, Cohen K, Myer L, Davies MA, Maartens G, Boulle A.

Clin Infect Dis. 2020 Jan 4. pii: ciz1224. doi: 10.1093/cid/ciz1224. [Epub ahead of print]

PMID:
31900473
4.

Peer Mentorship via Mobile Phones for Newly Diagnosed HIV-Positive Youths in Clinic Care in Khayelitsha, South Africa: Mixed Methods Study.

Hacking D, Mgengwana-Mbakaza Z, Cassidy T, Runeyi P, Duran LT, Mathys RH, Boulle A.

J Med Internet Res. 2019 Dec 10;21(12):e14012. doi: 10.2196/14012.

5.

Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006-2017.

Iyun V, Technau KG, Eley B, Rabie H, Boulle A, Fatti G, Egger M, Tanser F, Wood R, Fairlie L, Cotton MF, Davies MA.

Pediatr Infect Dis J. 2020 Feb;39(2):127-133. doi: 10.1097/INF.0000000000002516.

PMID:
31725119
6.

Quantifying the HIV treatment cascade in a South African health sub-district by gender: retrospective cohort study.

Lurie MN, Kirwa K, Callaway J, Cornell M, Boulle A, Bengtson AM, Smith M, Leon N, Colvin C.

Trop Med Int Health. 2020 Feb;25(2):186-192. doi: 10.1111/tmi.13334. Epub 2019 Nov 21.

PMID:
31698524
7.

Feasibility of antiretroviral therapy initiation under the treat-all policy under routine conditions: a prospective cohort study from Eswatini.

Kerschberger B, Jobanputra K, Schomaker M, Kabore SM, Teck R, Mabhena E, Lukhele N, Rusch B, Boulle A, Ciglenecki I.

J Int AIDS Soc. 2019 Oct;22(10):e25401. doi: 10.1002/jia2.25401.

8.

A systematic review of qualitative evidence on factors enabling and deterring uptake of HIV self-testing in Africa.

Njau B, Covin C, Lisasi E, Damian D, Mushi D, Boulle A, Mathews C.

BMC Public Health. 2019 Oct 15;19(1):1289. doi: 10.1186/s12889-019-7685-1.

9.

Assessing rates and contextual predictors of 5-year mortality among HIV-infected and HIV-uninfected individuals following HIV testing in Durban, South Africa.

Bassett IV, Xu A, Giddy J, Bogart LM, Boulle A, Millham L, Losina E, Parker RA.

BMC Infect Dis. 2019 Aug 28;19(1):751. doi: 10.1186/s12879-019-4373-9.

10.

The effect of HIV and antiretroviral treatment on pregnancy rates in the Western Cape province of South Africa.

Johnson LF, Mutemaringa T, Heekes A, Boulle A.

J Infect Dis. 2019 Jul 23. pii: jiz362. doi: 10.1093/infdis/jiz362. [Epub ahead of print]

PMID:
31332437
11.

Decreased risk of HIV-associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and population-based analysis.

Kerschberger B, Schomaker M, Telnov A, Vambe D, Kisyeri N, Sikhondze W, Pasipamire L, Ngwenya SM, Rusch B, Ciglenecki I, Boulle A.

Trop Med Int Health. 2019 Sep;24(9):1114-1127. doi: 10.1111/tmi.13290. Epub 2019 Aug 7.

12.

Why South Africa urgently needs to support the development of pregnancy exposure registries.

Mehta U, Kalk E, Fairlie L, Boulle A, Rees H.

S Afr Med J. 2019 Apr 29;109(5):294-295. doi: 10.7196/SAMJ.2019.v109i5.14008. No abstract available.

13.

Programmatic outcomes and impact of rapid public sector antiretroviral therapy expansion in adults prior to introduction of the WHO treat-all approach in rural Eswatini.

Kerschberger B, Schomaker M, Ciglenecki I, Pasipamire L, Mabhena E, Telnov A, Rusch B, Lukhele N, Teck R, Boulle A.

Trop Med Int Health. 2019 Jun;24(6):701-714. doi: 10.1111/tmi.13234. Epub 2019 Apr 1.

14.

Trends in maternal and neonatal mortality in South Africa: a systematic review.

Damian DJ, Njau B, Lisasi E, Msuya SE, Boulle A.

Syst Rev. 2019 Mar 27;8(1):76. doi: 10.1186/s13643-019-0991-y.

15.

The Continuing Value of CD4 Cell Count Monitoring for Differential HIV Care and Surveillance.

Rice B, Boulle A, Schwarcz S, Shroufi A, Rutherford G, Hargreaves J.

JMIR Public Health Surveill. 2019 Mar 20;5(1):e11136. doi: 10.2196/11136.

16.

What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies.

Patten G, Schomaker M, Davies MA, Rabie H, van Zyl G, Technau K, Eley B, Boulle A, Van Dyke RB, Patel K, Sipambo N, Wood R, Tanser F, Giddy J, Cotton M, Nuttall J, Essack G, Karalius B, Seage G, Sawry S, Egger M, Fairlie L; for IeDEA Southern Africa.

Pediatr Infect Dis J. 2019 Apr;38(4):400-405. doi: 10.1097/INF.0000000000002156.

PMID:
30882732
17.

Stock-outs of antiretroviral and tuberculosis medicines in South Africa: A national cross-sectional survey.

Hwang B, Shroufi A, Gils T, Steele SJ, Grimsrud A, Boulle A, Yawa A, Stevenson S, Jankelowitz L, Versteeg-Mojanaga M, Govender I, Stephens J, Hill J, Duncan K, van Cutsem G.

PLoS One. 2019 Mar 12;14(3):e0212405. doi: 10.1371/journal.pone.0212405. eCollection 2019.

18.

How accurately do routinely reported HIV viral load suppression proportions reflect progress towards the 90-90-90 target in the population on antiretroviral treatment in Khayelitsha, South Africa?

Euvrard J, Schulz T, Hilderbrand K, Bosland M, Osler M, Boulle A, Davies MA.

S Afr Med J. 2019 Feb 26;109(3):174-177. doi: 10.7196/SAMJ.2019.v109i3.13456.

19.

The effects of add-on corticosteroids on renal outcomes in patients with biopsy proven HIV associated nephropathy: a single centre study from South Africa.

Wearne N, Swanepoel CR, Duffield MS, Davidson BJ, Manning K, Tiffin N, Boulle A, Rayner BL, Naidu P, Okpechi IG.

BMC Nephrol. 2019 Feb 6;20(1):44. doi: 10.1186/s12882-019-1208-2.

20.

Neonatal and infant diagnostic HIV-PCR uptake and associations during three sequential policy periods in Cape Town, South Africa: a longitudinal analysis.

Kalk E, Kroon M, Boulle A, Osler M, Euvrard J, Stinson K, Timmerman V, Davies MA.

J Int AIDS Soc. 2018 Nov;21(11):e25212. doi: 10.1002/jia2.25212.

21.

Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.

Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX.

AIDS. 2019 Mar 1;33(3):525-536. doi: 10.1097/QAD.0000000000002053.

22.

Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts.

de Waal R, Cohen K, Boulle A, Fox MP, Maartens G, Igumbor EU, Davies MA.

PLoS One. 2018 Sep 5;13(9):e0203530. doi: 10.1371/journal.pone.0203530. eCollection 2018.

23.

Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.

Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, Leslie J, Boulle A, Mudaly V, Kock Y, Meintjes G, Wasserman S.

Clin Infect Dis. 2019 Apr 24;68(9):1522-1529. doi: 10.1093/cid/ciy727.

24.
25.
26.

Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia.

Brennan AT, Bor J, Davies MA, Wandeler G, Prozesky H, Fatti G, Wood R, Stinson K, Tanser F, Bärnighausen T, Boulle A, Sikazwe I, Zanolini A, Fox MP.

Am J Epidemiol. 2018 Sep 1;187(9):1990-2001. doi: 10.1093/aje/kwy093.

27.

Self-enrolment antenatal health promotion data as an adjunct to maternal clinical information systems in the Western Cape Province of South Africa.

Heekes A, Tiffin N, Dane P, Mutemaringa T, Smith M, Zinyakatira N, Barron P, Seebregts C, Boulle A.

BMJ Glob Health. 2018 Apr 24;3(Suppl 2):e000565. doi: 10.1136/bmjgh-2017-000565. eCollection 2018. Review.

28.

Strengthening Routine Data Systems to Track the HIV Epidemic and Guide the Response in Sub-Saharan Africa.

Rice B, Boulle A, Baral S, Egger M, Mee P, Fearon E, Reniers G, Todd J, Schwarcz S, Weir S, Rutherford G, Hargreaves J.

JMIR Public Health Surveill. 2018 Apr 3;4(2):e36. doi: 10.2196/publichealth.9344.

29.

The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa.

Osler M, Hilderbrand K, Goemaere E, Ford N, Smith M, Meintjes G, Kruger J, Govender NP, Boulle A.

Clin Infect Dis. 2018 Mar 4;66(suppl_2):S118-S125. doi: 10.1093/cid/cix1140.

30.

Seasonal variations in tuberculosis diagnosis among HIV-positive individuals in Southern Africa: analysis of cohort studies at antiretroviral treatment programmes.

Ballif M, Zürcher K, Reid SE, Boulle A, Fox MP, Prozesky HW, Chimbetete C, Zwahlen M, Egger M, Fenner L; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA).

BMJ Open. 2018 Jan 11;8(1):e017405. doi: 10.1136/bmjopen-2017-017405.

31.

Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania.

Semvua SK, Orrell C, Mmbaga BT, Semvua HH, Bartlett JA, Boulle AA.

PLoS One. 2017 Dec 18;12(12):e0189460. doi: 10.1371/journal.pone.0189460. eCollection 2017.

32.

Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study.

Johnson LF, May MT, Dorrington RE, Cornell M, Boulle A, Egger M, Davies MA.

PLoS Med. 2017 Dec 12;14(12):e1002468. doi: 10.1371/journal.pmed.1002468. eCollection 2017 Dec.

33.

Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes.

Rohr JK, Ive P, Horsburgh CR, Berhanu R, Hoffmann CJ, Wood R, Boulle A, Giddy J, Prozesky H, Vinikoor M, Mwanza MW, Wandeler G, Davies MA, Fox MP.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):413-416. doi: 10.1097/QAI.0000000000001611.

34.

Pharmacovigilance: A public health priority for South Africa.

Mehta U, Kalk E, Boulle A, Nkambule P, Gouws J, Rees H, Cohen K.

S Afr Health Rev. 2017;2017:125-133. Epub 2017 Aug 23.

35.

Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study.

Kaplan SR, Oosthuizen C, Stinson K, Little F, Euvrard J, Schomaker M, Osler M, Hilderbrand K, Boulle A, Meintjes G.

PLoS Med. 2017 Nov 7;14(11):e1002407. doi: 10.1371/journal.pmed.1002407. eCollection 2017 Nov.

36.

Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.

Cornell M, Johnson LF, Wood R, Tanser F, Fox MP, Prozesky H, Schomaker M, Egger M, Davies MA, Boulle A; International Epidemiology Databases to Evaluate AIDS-Southern Africa collaboration.

J Int AIDS Soc. 2017 Sep 25;20(1):21902. doi: 10.7448/IAS.20.1.21902.

37.

Trends in maternal and neonatal mortality in South Africa: a systematic review protocol.

Damian DJ, Njau B, Lisasi E, Msuya SE, Boulle A.

Syst Rev. 2017 Aug 17;6(1):165. doi: 10.1186/s13643-017-0560-1.

38.

High rates of retention and viral suppression in the scale-up of antiretroviral therapy adherence clubs in Cape Town, South Africa.

Tsondai PR, Wilkinson LS, Grimsrud A, Mdlalo PT, Ullauri A, Boulle A.

J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21649. doi: 10.7448/IAS.20.5.21649.

39.

Feasibility of Establishing HIV Case-Based Surveillance to Measure Progress Along the Health Sector Cascade: Situational Assessments in Tanzania, South Africa, and Kenya.

Harklerode R, Schwarcz S, Hargreaves J, Boulle A, Todd J, Xueref S, Rice B.

JMIR Public Health Surveill. 2017 Jul 10;3(3):e44. doi: 10.2196/publichealth.7610.

40.

HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies.

Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, Ballif M, Furrer H, Zwahlen M, Davies MA, Egger M; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA).

J Int AIDS Soc. 2017 Jun 23;20(1):21327. doi: 10.7448/IAS.20.1.21327.

41.

Where do HIV-infected adolescents go after transfer? - Tracking transition/transfer of HIV-infected adolescents using linkage of cohort data to a health information system platform.

Davies MA, Tsondai P, Tiffin N, Eley B, Rabie H, Euvrard J, Orrell C, Prozesky H, Wood R, Cogill D, Haas AD, Sohn AH, Boulle A.

J Int AIDS Soc. 2017 May 16;20(Suppl 3):21668. doi: 10.7448/IAS.20.4.21668.

42.

Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.

De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA.

J Int AIDS Soc. 2017 Apr 10;20(1):21317. doi: 10.7448/IAS.20.01/21317. Erratum in: J Int AIDS Soc. 2017 Jun 2;20(1):22066.

43.

Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort.

Lawn SD, Kerkhoff AD, Burton R, Schutz C, Boulle A, Vogt M, Gupta-Wright A, Nicol MP, Meintjes G.

BMC Med. 2017 Mar 21;15(1):67. doi: 10.1186/s12916-017-0822-8.

44.

First-line antiretroviral drug discontinuations in children.

Fortuin-de Smidt M, de Waal R, Cohen K, Technau KG, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA.

PLoS One. 2017 Feb 13;12(2):e0169762. doi: 10.1371/journal.pone.0169762. eCollection 2017.

45.

Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.

Stewart A, Lehloenya R, Boulle A, de Waal R, Maartens G, Cohen K.

Pharmacoepidemiol Drug Saf. 2016 Nov;25(11):1313-1319. doi: 10.1002/pds.4067. Epub 2016 Jul 27.

PMID:
27464823
46.

Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?

Brennan AT, Davies MA, Bor J, Wandeler G, Stinson K, Wood R, Prozesky H, Tanser F, Fatti G, Boulle A, Sikazwe I, Wool-Kaloustian K, Yuannoutsos C, Leroy V, de Rekeneire N, Fox MP.

AIDS. 2017 Jan 2;31(1):147-157.

47.

Life expectancy trends in adults on antiretroviral treatment in South Africa.

Johnson LF, Keiser O, Fox MP, Tanser F, Cornell M, Hoffmann CJ, Prozesky H, Boulle A, Davies MA; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration.

AIDS. 2016 Oct 23;30(16):2545-2550.

48.

Statistical Nature of Atomic Disorder in Irradiated Crystals.

Boulle A, Debelle A.

Phys Rev Lett. 2016 Jun 17;116(24):245501. doi: 10.1103/PhysRevLett.116.245501. Epub 2016 Jun 16.

PMID:
27367393
49.

Prospects for HIV control in South Africa: a model-based analysis.

Johnson LF, Chiu C, Myer L, Davies MA, Dorrington RE, Bekker LG, Boulle A, Meyer-Rath G.

Glob Health Action. 2016 Jun 8;9:30314. doi: 10.3402/gha.v9.30314. eCollection 2016.

50.

Cohort Profile: The Khayelitsha antiretroviral programme, Cape Town, South Africa.

Stinson K, Goemaere E, Coetzee D, van Cutsem G, Hilderbrand K, Osler M, Hennessey C, Wilkinson L, Patten G, Cragg C, Mathee S, Cox V, Boulle A.

Int J Epidemiol. 2017 Apr 1;46(2):e21. doi: 10.1093/ije/dyw057. No abstract available.

PMID:
27208042

Supplemental Content

Loading ...
Support Center